




Sociedad Española
de Reumatología -
Colegio Mexicano
de Reumatología

Reumatología Clínica

www.reumatologiaclinica.org



Brief Report

Treat-to-target strategy in patients with rheumatoid arthritis: Audit of adherence from real world clinical data



José-Luis Andréu^{a,*}, María Auxiliadora Martín^b, Héctor Corominas^c,
José Javier Pérez-Venegas^d, José Andrés Román-Ivorra^e, Fernando Sánchez-Alonso^b,
Ángel Gil de Miguel^f

^a Rheumatology Department, H.U. Puerta de Hierro Majadahonda, Majadahonda, Spain

^b Research Unit, Sociedad Española de Reumatología, Madrid, Spain

^c Unitat territorial de Reumatologia, Hospital Universitari de Sant Pau & Hospital Dos de Maig, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain

^d Rheumatology Department, H.C.U. Virgen Macarena, Sevilla, Spain

^e Rheumatology Department, H.U.P. La Fe, Valencia, Spain

^f Cátedra de Medicina Preventiva y Salud Pública, Universidad Rey Juan Carlos, Madrid, Spain

ARTICLE INFO

Article history:

Received 15 October 2019

Accepted 31 October 2019

Keywords:

Rheumatoid arthritis

Treat-to-target

ABSTRACT

Introduction: The current paradigm of the management of rheumatoid arthritis (RA) recommends achieving a state of remission or low disease activity through the treat-to-target strategy. Our study assesses adherence to this strategy.

Method: Patients with RA (ACR-EULAR 2010 criteria) were included. From each centre, 19 patients were randomly selected. Clinical histories (CH) were assessed by independent auditors, checking compliance with predefined quality criteria. The study was approved by ethics committees.

Results: We included 856 patients (mean age 54 years; 71% women). The use of a combined index (CI) was recorded in 61% of cases. Visits were recorded every 4 weeks using a CI in 4% of CH while attempts were made to achieve remission. Monitoring of disease activity every 6–8 months after reaching the target was recorded in 73% of cases.

Conclusions: The implementation of the treat-to-target strategy is barely recorded in patients with RA in routine clinical practice.

© 2019 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.

Estrategia de tratar por objetivos en pacientes con artritis reumatoide: auditoría de la adherencia en práctica clínica habitual

RESUMEN

Introducción: El paradigma actual del manejo de la artritis reumatoide (AR) recomienda alcanzar un estado de remisión o baja actividad mediante la estrategia de «tratar por objetivos». Nuestro estudio evalúa la adhesión a esta estrategia.

Método: Se incluyeron pacientes con AR (criterios ACR-EULAR 2010). De cada centro, se eligieron al azar 19 pacientes. Auditores independientes evaluaron las historias clínicas (HC), verificando el cumplimiento de criterios de calidad predefinidos. El estudio fue aprobado por los comités de ética.

Resultados: Se incluyeron 856 pacientes (edad media, 54 años; 71% mujeres). El uso de un índice combinado (IC) se recogió en el 61% de los casos. En el 4% de las HC se registraron visitas cada 4 semanas utilizando un IC mientras se intentaba alcanzar la remisión. La monitorización de actividad cada 6-8 meses tras alcanzar el objetivo se registró en el 73% de los casos.

Palabras clave:

Artritis reumatoide

Terapia por objetivos

* Corresponding author.

E-mail address: jlandreus@gmail.com (J.-L. Andréu).

Conclusiones: La implementación de la estrategia de «tratar por objetivos» apenas está registrada en pacientes con AR en práctica clínica habitual.

© 2019 Elsevier España, S.L.U. y Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. Todos los derechos reservados.

Introduction

Rheumatoid arthritis (RA) is a systemic autoimmune disease whose main characteristic is a chronic inflammation of diarthrodial joints. In absence of a successful therapy, RA leads to irreversible destruction of articular structure, functional impairment and loss of quality of life.

With the advent of biologic therapy and the optimal use of conventional disease-modifying anti-rheumatic drugs (DMARDs), being methotrexate (MTX) the corner-stone of RA treatment, remission of disease or, at least, a state of low disease activity (LDA) are considered nowadays realistic goals in the management of RA, as different guidelines and recommendations suggest.^{1–3}

Several studies have compared standard of care by personal rheumatologist's judgement deciding the changes in therapy versus tight control and dynamic escalation of the therapy according to pre-specified therapeutic targets.^{4–7} These studies have demonstrated better outcomes with the so called “treat to target” (TTT) strategies. Thus, the current paradigm of optimal clinical care of patients with RA recommends reaching a state of remission or LDA of the disease, assessed by composite indexes of activity, by means of a tight control and a dynamic adjustment of available therapeutic options, using a TTT strategy.^{8,9}

Although the TTT strategy is widely known and assumed by rheumatologists as beneficial and feasible,^{10–12} there are barriers in routine clinical practice that could hinder its wide implementation and the optimal management of RA patients. The objective of our study was to objectively assess the level of implementation of the TTT recommendations in routine clinical care of RA patients.

Methods

This study is an audit of clinical records of patients diagnosed of RA and managed in Spanish rheumatology units.

All the rheumatology units of Spain were invited to participate in the study. Those units that accepted to participate sent to the research team a computerized anonymized list of adult patients fulfilling the 2010 ACR-EULAR criteria for RA¹³ and diagnosed of RA between January 1st, 2010 and December 31st, 2013.

In order to accomplish an adequate representation of the RA population, 19 patients were randomly chosen from the list provided by every department.

Independent auditors, specifically trained by the research team, assessed the clinical records, verifying the fulfilling of the TTT recommendations in the management of the patients. Clinical, epidemiological and demographic data were recorded from every patient.

The study was approved by the ethic committees of every participant hospital. Descriptive statistics was used for the presentation of the results.

Results

Forty-six rheumatology units participated in the study. From them, a total of 856 clinical records, randomly chosen, were available for the audit. [Table 1](#) shows the characteristics of the

Table 1

Characteristics of the patients included in the study.

Gender	71% female
Mean (\pm SD) age (years)	54.3 (\pm 15.6)
Mean (\pm SD) disease duration (years)	2.1 (\pm 1.1)
RF+	98%
ACPA+	90%
DAS28esr at first consultation (mean \pm SD)	4.5 (\pm 1.5)
DAS28esr <3.2 or SDAI \leq 11 in follow-up	38%
DAS28esr <2.6 or SDAI \leq 3.3 in follow-up	28%

Abbreviations: ACPA, anti-citrullinated peptides antibodies; DAS28esr, disease activity index based on erythrocyte sedimentation rate; RF, rheumatoid factor.

patients. Mean age of them was 54 years and 71% of patients were women. Mean duration of RA was 2 years.

An explicit assessment of the disease activity as a determinant element considered to select the therapy was recorded in 32% of the CRs. Use of at least a composite disease activity score (DAS28, SDAI or CDAI) was recorded in 61% of the cases. In the follow-up, 38% of patients reached a state of low disease activity, defined by a DAS28 <3.2 and/or a SDAI \leq 11.

In only 4% of the CRs, appointments every 4 weeks using a composite activity score had been recorded during the early stage while trying to reach remission after the diagnosis of RA.

Disease activity monitoring every 6–8 months after reaching the therapeutic target was recorded in 73% of the cases.

In 99% of the cases, the clinicians had registered patient's comorbidities and these associated conditions had been considered in planning the therapeutic approach and objective.

Discussion

Our data have shown a low implementation of the TTT strategy in the routine clinical practice of the rheumatology units participating in the study. The data are somewhat disappointing since the widespread dissemination of TTT strategy and the acceptance of their feasibility by rheumatologists¹⁴ would lead to the expectation of a wider implementation of this treatment strategy.

There are several barriers that have been suggested for the implementation of the TTT strategy.¹⁵ Likely, the main ones are the lack of time in real world clinical practice to use the compound indices of activity and the difficulty to get appointments for the patients with RA month by month during the escalation of medication to achieve a state of remission or, at least, LDA. A potential solution would be to maintain preferential citation slots in order to monitor patients every 1–3 months. This would require an additional effort in rheumatologist resources but, on the other hand, the TTT strategy has been shown to be more effective than usual care¹⁶ and even cost-efficient in the medium and long term.¹⁷

Although our results are quite disappointing, we used a very stringent criterion, four weeks, to judge whether the TTT strategy was being followed. Likely, the results would not have been so poor if we had used 3 months instead of 4 weeks as the criterion of excellence to adjust the treatment of patients with RA during the escalation of therapy in order to reach a state of remission or LDA.

In conclusion, a minority of the patients with RA are managed according to the TTT strategy, that is, using combined indices of

activity to monitor the response to treatment and follow-up every 4 weeks until the therapeutic goal is achieved.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Compliance with ethical standards

This study was funded by an unrestricted grant provided by the biopharmaceutical company AbbVie.

Conflict of interests

The authors declare no conflict of interest. Ángel Gil de Miguel declares that he is Director of the Chair of Evaluation of Health Outcomes Universidad Rey Juan Carlos/AbbVie.

Acknowledgements

We thank to the Rheumatology units that accepted to be audited their help in the evaluation of clinical records and their commitment in the identification of areas of improvement in the management of RA patients.

References

- Sanmartí R, García-Rodríguez S, Álvaro-Gracia JM, Andreu JL, Balsa A, Cáliz R, et al. 2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis. *Reumatol Clin.* 2015;11:279–94.
- Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis Rheumatol.* 2016;68:1–26.
- Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. *Ann Rheum Dis.* 2017;76:960–77.
- Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. *Lancet.* 2004;364:263–9.
- Verstappen SM, Jacobs JW, van der Veen MJ, Heurkens AHM, Schenk Y, ter Borg EJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). *Ann Rheum Dis.* 2007;66:1443–9.
- Fransen J, Moens HB, Speyer I, van Riel PL. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised control trial. *Ann Rheum Dis.* 2005;64:1294–8.
- Symmons D, Tricker K, Roberts C, Davies L, Dawes P, Scott DL. The British Rheumatoid Outcome Study Group (BROSG) randomised controlled trial to compare the effectiveness and cost-effectiveness of aggressive versus symptomatic therapy in established rheumatoid arthritis. *Health Technol Assess.* 2005;9, iii–iv, ix–x, 1–78.
- Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. *Ann Rheum Dis.* 2010;69:631–7.
- Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. *Ann Rheum Dis.* 2016;75:3–15.
- Haraoui B, Smolen JS, Aletaha D, Breedveld FC, Burmester G, Codreanu C, et al. Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire. *Ann Rheum Dis.* 2011;70:1999–2002.
- Haraoui B, Bensen W, Bessette L, Le Clercq S, Thorne C, Wade J. Treating rheumatoid arthritis to target: a Canadian physician survey. *J Rheumatol.* 2012;39:949–53.
- Caporali R, Conti F, Covelli M, Govoni M, Salaffi F, Ventriglia G, et al. Treating rheumatoid arthritis to target: an Italian rheumatologists' survey on the acceptance of the treat-to-target recommendations. *Clin Exp Rheumatol.* 2014;32:471–6.
- Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Ann Rheum Dis.* 2010;69:1580–8.
- Vermeer M, Kuper HH, Bernelot Moens HJ, Hoekstra M, Posthumus MD, van Riel PL, et al. Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort. *Arthritis Res Ther.* 2012;14:R254.
- Ford JA, Solomon DH. Challenges in implementing treat-to-target strategies in rheumatology. *Rheum Dis Clin North Am.* 2019;45:101–12.
- Schipper LG, Vermeer M, Kuper HH, Hoekstra MO, Haagsma CJ, Den Broeder AA, et al. A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry. *Ann Rheum Dis.* 2012;71:845–50.
- Vermeer M, Kievit W, Kuper HH, Braakman-Jansen LM, Bernelot Moens HJ, Zijlstra TR, et al. Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry. *BMC Musculoskelet Disord.* 2013;14:350.